The company has developed a CE-marked medical device for reduction of blood group A and blood group B specific antibodies (UBP-product).

Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in this setting, however the availability of blood group O whole blood with low levels (titers) of blood group antibodies (anti-A/B antibodies) is limited. Thus, products or methods for the manufacturing of LTOWB for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts.

The company's UBP-product has been tested at the University of Rochester Medical Center (U.S.) for this very purpose: to reduce anti-A/B antibody titers in blood group O whole blood.

The results1 are encouraging as they show that the UBP-product is effective in reducing anti-A/B antibody titers in whole blood units to near zero, without effecting other blood parameters as tested by the complete blood count or thromboelastography assays.

The authors conclude that the product “…could be readily and routinely used at blood collection center or transfusion facilities without extensive training. Preparation of LTOWB could have clinical value in massive transfusion in both civilian and military settings.”

(1)    Gupta G, Henrichs K, Nilsson K, Wagner S, Brown B, Masel D, Refaai M, Blumberg N; Reduction of Anti-A and Anti-B Isoagglutinin Titers of Group O Whole Blood Units with the Glycosorb® ABO Column Anesthesia & Analgesia. 133(3S):1-106, September 2021 (P 25).

The results will also be presented at the AABB congress in October 2021.

Johan Nilsson, Interim CEO, Glycorex Transplantation AB.
E-mail:, phone: 046-286 52 30

The information was submitted for publication, through the agency of the contact person, on September 24, 2021 17:15 CET.

Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.